Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab in Nonresponsive Celiac Disease
NCT06557772Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial of amlitelimab in celiac disease (6 arms), sponsored by Sanofi. Primary endpoint: Villus Height to Crypt Depth Ratio at Week 28. Started Aug 2024; status: active, not recruiting.
02
Drugs
amlitelimab
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT06557772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557772.